U.S. Olympic gold medal-winning athlete Lindsey Vonn is teaming up again with infectious disease biopharmaceutical company Invivid for a new campaign centered around antibody-based treatments.
The Antibodies for Every Body initiative is a national campaign established to educate the public about the use of antibodies to protect against disease.
Invivid said in an April 7 statement that it chose Vonn because her career has been “defined by training with intention, overcoming challenges, and caring for your body from the inside out.”
The campaign features the digital footprint of AntibodiesforAnyBody.com, an educational site focused on the function of antibodies.
Also included is the “Antibodies for Any Body Wellness Assessment,” an interactive tool that shows how lifestyle habits can help with antibody production.
Bonn and Invivid originally signed a cooperation agreement in January, when Bonn was preparing for her fifth Winter Olympics in Italy. This came after the Olympian was able to reverse his previous competitive retirement following knee replacement surgery in 2024.
This wasn’t her first foray into the world of pharmaceutical marketing either. Four years ago, Bonn also signed up as one of several spokespeople for insomnia drug maker Idorsia and its sleeping drug Kvivic.
Vonn was hoping to bring her medal hopes home in the downhill event at this year’s Winter Olympics, but she sustained a severe compound foot and ankle fracture during a run that required multiple surgeries to repair.
lindsay vonn
(invitation)
Regarding the incident, Invivid said, “While this campaign partnership began before her recent accident and subsequent recovery journey, the core message of this initiative – empowering individuals to understand and support their own immune health – remains central to Vonn’s wellness philosophy.”
Invivyd was born as Adagio Therapeutics in 2020 during the COVID-19 pandemic and changed to its current name in 2022.
After several roller coaster years of getting the first antibody-based coronavirus prevention and treatment drug across the FDA finish line, Invivid finally secured emergency use authorization in March 2024 for another monoclonal antibody (now known as Pemgarda) for pre-exposure prophylaxis.
Additionally, the company is in early development of antibody-based treatments for the long-lasting coronavirus, RSV, and measles, according to its online pipeline.
